Edgewise Therapeutics initiates EDG-7500 Phase 1 trial targeting cardiac diseases

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a biopharmaceutical company specializing in muscle diseases, announced the commencement of its Phase 1 trial for EDG-7500. This oral, selective, ... Read More